| 1.315 0.035 (2.73%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.79 | 1-year : | 1.98 |
| Resists | First : | 1.53 | Second : | 1.7 |
| Pivot price | 1.48 |
|||
| Supports | First : | 1.27 | Second : | 1.06 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.48 |
| MA(100) : | 1.45  |
MA(250) : | 1.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 9.9 |
| RSI | RSI(14): 34.2 |
|||
| 52-week | High : | 2.98 | Low : | 1.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARTL ] has closed above bottom band by 7.7%. Bollinger Bands are 75% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.4 | 1.4 - 1.41 |
| Low: | 1.26 - 1.27 | 1.27 - 1.28 |
| Close: | 1.3 - 1.32 | 1.32 - 1.33 |
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Wed, 17 Apr 2024
CSL (OTCMKTS:CSLLY) versus Artelo Biosciences (NASDAQ:ARTL) Head-To-Head Contrast - Defense World
Mon, 25 Mar 2024
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023 - InvestorPlace
Tue, 12 Mar 2024
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge - Yahoo Finance
Fri, 08 Sep 2023
Artelo plans IND filing for FABP5 inhibitor ART-26.12 for neuropathic pain following FDA guidance - BioWorld Online
Wed, 08 Dec 2021
Artelo Biosciences Inc. (NASDAQ: ARTL) Announce Fiscal Year 2021 Results And Updates On ART27.13 Study - BP Journal
Fri, 12 Feb 2021
ARTL Stock Alert: The Big Reason Biopharma Artelo Biosciences Is Rocketing Today - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 19 (K) |
| EPS | -3.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.1 % |
| Return on Equity (ttm) | -59.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|